Department of Medicine, Division of Nephrology, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland.
Department of Nephrology and Dialysis, Ospedale Parodi, Delfino, Colleferro, 00034 Rome, Italy.
Cells. 2021 May 3;10(5):1091. doi: 10.3390/cells10051091.
: It is estimated that chronic kidney disease (CKD) accounts globally for 5 to 10 million deaths annually, mainly due to cardiovascular (CV) diseases. Traditional as well as non-traditional CV risk factors such as vascular calcification are believed to drive this disproportionate risk burden. We aimed to investigate the association of coronary artery calcification (CAC) progression with all-cause mortality in patients new to hemodialysis (HD). : Post hoc analysis of the Independent study (NCT00710788). At study inception and after 12 months of follow-up, 414 patients underwent computed tomography imaging for quantification of CAC via the Agatston methods. The square root method was used to assess CAC progression (CACP), and survival analyses were used to test its association with mortality. : Over a median follow-up of 36 months, 106 patients died from all causes. Expired patients were older, more likely to be diabetic or to have experienced an atherosclerotic CV event, and exhibited a significantly greater CAC burden ( = 0.002). Survival analyses confirmed an independent association of CAC burden (hazard ratio: 1.29; 95% confidence interval: 1.17-1.44) and CACP (HR: 5.16; 2.61-10.21) with all-cause mortality. CACP mitigated the risk associated with CAC burden ( = 0.002), and adjustment for calcium-free phosphate binder attenuated the strength of the link between CACP and mortality. : CAC burden and CACP predict mortality in incident to dialysis patients. However, CACP reduced the risk associated with baseline CAC, and calcium-free phosphate binders attenuated the association of CACP and outcomes, suggesting that CACP modulation may improve survival in this population. Future endeavors are needed to confirm whether drugs or kidney transplantation may attenuate CACP and improve survival in HD patients.
据估计,慢性肾脏病(CKD)每年在全球造成 500 万至 1000 万人死亡,主要归因于心血管(CV)疾病。传统和非传统的 CV 危险因素,如血管钙化,被认为是导致这种不成比例的风险负担的原因。我们旨在研究新开始血液透析(HD)的患者的冠状动脉钙化(CAC)进展与全因死亡率之间的关系。
该研究是独立研究(NCT00710788)的事后分析。在研究开始时和随访 12 个月后,414 名患者接受了计算机断层扫描成像,通过 Agatston 方法对 CAC 进行定量分析。平方根法用于评估 CAC 进展(CACP),并使用生存分析来检验其与死亡率的关系。
在中位数为 36 个月的随访期间,106 名患者死于各种原因。死亡患者年龄较大,更有可能患有糖尿病或经历过动脉粥样硬化性 CV 事件,并且 CAC 负担明显更大( = 0.002)。生存分析证实 CAC 负担(危险比:1.29;95%置信区间:1.17-1.44)和 CACP(HR:5.16;2.61-10.21)与全因死亡率独立相关。CACP 减轻了 CAC 负担相关的风险( = 0.002),并且调整无钙磷酸盐结合剂减弱了 CACP 与死亡率之间的联系强度。
CAC 负担和 CACP 可预测新开始透析患者的死亡率。然而,CACP 降低了与基线 CAC 相关的风险,无钙磷酸盐结合剂减弱了 CACP 与结局的关联,表明 CACP 调节可能改善该人群的生存。需要进一步的研究来证实药物或肾移植是否可以减轻 CACP 并改善 HD 患者的生存。